SG HealthCare Co Ltd

SG HealthCare maintains a conservative capital structure with a debt-to-equity ratio of 0.37, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.74, suggesting it can cover short-term obligations but with limited excess capacity. However, the company's operating cash flow is negative at -4,598.49 million KRW, and free cash flow is also negative at -969.15 million KRW, signaling potential near-term liquidity constraints. Profitability metrics show a return on equity (ROE) of 3.91% and a return on assets (ROA) of 2.31%, both below the industry median for medical equipment manufacturers. The company's operating margin is 6.0% (1,473.28 million KRW / 24,601.05 million KRW revenue), which is modest compared to peers. Gross margin stands at 28.9% (7,116.22 million KRW / 24,601.05 million KRW revenue), indicating moderate cost control in production. The company's revenue is concentrated in a single business segment focused on medical imaging diagnostic equipment, with no disclosed geographic diversification. This lack of segment or geographic diversification increases exposure to sector-specific risks and regional economic fluctuations. Looking ahead, the company is projected to grow revenue by 4.2% in the current fiscal year and 3.8% in the next, based on industry demand for diagnostic imaging equipment and the company's product portfolio. However, the growth trajectory is constrained by the company's negative free cash flow and limited capital expenditure of -2,650.12 million KRW, which may hinder R&D and market expansion. Risk factors include medium liquidity risk due to negative operating and free cash flows, and a net cash position that is negative after subtracting total debt. The company's dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. However, the company's reliance on a single product line and geographic market increases vulnerability to supply chain disruptions and regulatory changes. Recent filings and transcripts indicate the company is focused on expanding its MRI accelerating solution (IAI) software offerings and enhancing technical support services. No major regulatory or litigation risks were disclosed in the latest 10-K or earnings call transcripts.